Tarek Abdulhadi

Dr. Tarek Abdulhadi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FAFarah Abuazzam
Farah Abuazzam
CDCasey Dubrawka
Casey Dubrawka
TATarek Abdulhadi
Tarek Abdulhadi
GAGwendolyn Amurao
Gwendolyn Amurao
LALouai Alrata
Louai Alrata
TATarek Alhamad
Tarek Alhamad
Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.

21 September 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
TATarek Abdulhadi
Tarek Abdulhadi
LALouai Alrata
Louai Alrata
CDCasey Dubrawka
Casey Dubrawka
GAGwendolyn Amurao
Gwendolyn Amurao
SKSri Mahathi Kalipatnapu
Sri Mahathi Kalipatnapu
TATarek Alhamad
Tarek Alhamad
The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft s...